IL147246A0 - Highly selective norepinephrine reuptake inhibitors and methods of using the same - Google Patents

Highly selective norepinephrine reuptake inhibitors and methods of using the same

Info

Publication number
IL147246A0
IL147246A0 IL14724600A IL14724600A IL147246A0 IL 147246 A0 IL147246 A0 IL 147246A0 IL 14724600 A IL14724600 A IL 14724600A IL 14724600 A IL14724600 A IL 14724600A IL 147246 A0 IL147246 A0 IL 147246A0
Authority
IL
Israel
Prior art keywords
methods
same
highly selective
reuptake inhibitors
norepinephrine reuptake
Prior art date
Application number
IL14724600A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL147246(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL147246A0 publication Critical patent/IL147246A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14724600A 1999-07-01 2000-06-22 Highly selective norepinephrine reuptake inhibitors and methods of using the same IL147246A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US14413199P 1999-07-16 1999-07-16
US15825699P 1999-10-06 1999-10-06
US17038199P 1999-12-13 1999-12-13
PCT/US2000/017256 WO2001001973A2 (fr) 1999-07-01 2000-06-22 Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation

Publications (1)

Publication Number Publication Date
IL147246A0 true IL147246A0 (en) 2002-08-14

Family

ID=27495506

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14724600A IL147246A0 (en) 1999-07-01 2000-06-22 Highly selective norepinephrine reuptake inhibitors and methods of using the same
IL187513A IL187513A0 (en) 1999-07-01 2007-11-20 Use of (s,s)-reboxetine in the treatment of pain conditions and incontinence
IL187512A IL187512A0 (en) 1999-07-01 2007-11-20 Use of (s,s)-reboxetine in the treatment of pain conditions and incontinence

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL187513A IL187513A0 (en) 1999-07-01 2007-11-20 Use of (s,s)-reboxetine in the treatment of pain conditions and incontinence
IL187512A IL187512A0 (en) 1999-07-01 2007-11-20 Use of (s,s)-reboxetine in the treatment of pain conditions and incontinence

Country Status (31)

Country Link
US (18) US6465458B1 (fr)
EP (3) EP2087892A3 (fr)
JP (3) JP2003503450A (fr)
KR (5) KR100948757B1 (fr)
CN (5) CN1660109A (fr)
AR (1) AR035158A1 (fr)
AT (9) ATE364386T1 (fr)
AU (2) AU771258B2 (fr)
BR (1) BR0012136A (fr)
CA (2) CA2375908C (fr)
CL (3) CL2008002866A1 (fr)
CO (1) CO5190662A1 (fr)
CZ (1) CZ299847B6 (fr)
DE (9) DE60026627T2 (fr)
DK (4) DK1632234T3 (fr)
EA (6) EA011094B1 (fr)
ES (9) ES2258010T3 (fr)
GE (1) GEP20094798B (fr)
HK (2) HK1049630A1 (fr)
HU (1) HUP0201623A3 (fr)
IL (3) IL147246A0 (fr)
MX (1) MXPA02000562A (fr)
MY (1) MY137348A (fr)
NO (4) NO20016406L (fr)
NZ (2) NZ533243A (fr)
PE (1) PE20010684A1 (fr)
PL (1) PL196996B1 (fr)
PT (5) PT1632234E (fr)
SK (5) SK286667B6 (fr)
TW (9) TWI245631B (fr)
WO (1) WO2001001973A2 (fr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1660109A (zh) 1999-07-01 2005-08-31 法玛西雅厄普约翰美国公司 高度选择性去甲肾上腺素再摄取抑制剂及其用途
DE60034815T2 (de) * 1999-12-01 2008-01-31 Ucb S.A. Ein pyrrolidinacetatderivat zur behandlung von chronischem oder neuropathischem schmerz
CA2404704A1 (fr) * 2000-04-21 2001-11-22 David W. Robertson Traitement de la cellulomyalgie et du syndrome de fatigue chronique
EP1274430B1 (fr) 2000-04-21 2005-12-14 Pharmacia & Upjohn Company LLC Cabergoline destinee au traitement de la fibromyalgie et du syndrome de fatigue chronique
EP1333835A1 (fr) * 2000-10-31 2003-08-13 Head Explorer A/S Utilisation d'inhibiteurs selectifs de recaptage de noradrenaline dans le traitement de la cephalee par tension nerveuse
AU2002217757A1 (en) * 2000-11-15 2002-05-27 Eli Lilly And Company Treatment of anxiety disorders
WO2002083141A1 (fr) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Traitement de la fibromyalgie et du syndrome de la fatigue chronique
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
JP4205577B2 (ja) * 2001-06-19 2009-01-07 ミュラー,ノルベルト 精神分裂病、妄想障害、情動障害、自閉症またはチック障害の治療のためのcox−2阻害薬の使用
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
ES2287338T3 (es) * 2001-11-30 2007-12-16 Eli Lilly And Company Uso de inhibidores de recaptacion de norepinefrina para el tratamiento de trastornos de tics.
BR0213581A (pt) * 2001-12-11 2004-08-24 Lilly Co Eli Uso de um inibidor de recaptação de norepinefrina seletivo
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
CA2475763A1 (fr) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methodes de traitement du trouble d'hyperactivite avec deficit de l'attention (thada)
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
JP4545584B2 (ja) 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
CN101444509A (zh) * 2002-05-30 2009-06-03 神经研究公司 治疗慢性疼痛的三单胺再摄取抑制剂
AU2003227755B2 (en) * 2002-06-17 2009-01-15 Pfizer Italia S.R.L. Pharmaceutical salts of reboxetine
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
BR0313411A (pt) * 2002-08-14 2005-06-28 Pharmacia & Upjohn Co Llc Uso de reboxetina para o tratamento de ondas de calor
ATE327982T1 (de) 2002-08-23 2006-06-15 Lilly Co Eli Benzylmorpholinderivate
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
DE60324685D1 (de) 2002-08-23 2008-12-24 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
EP1558231A4 (fr) * 2002-10-03 2010-09-08 Cypress Bioscience Inc Escalade posologique et dose quotidienne fractionnee d'antidepresseurs pour traiter des troubles neurologiques
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
JP2006516976A (ja) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ,インコーポレイテッド 機能性腸障害を処置する方法
ATE359079T1 (de) * 2003-01-13 2007-05-15 Dynogen Pharmaceuticals Inc Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
CA2519379A1 (fr) * 2003-04-04 2004-10-21 Dynogen Pharmaceuticals, Inc. Methode de traitement de troubles des voies urinaires inferieures
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
WO2004105690A2 (fr) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Traitement de douleurs chroniques au moyen de chimiotherapie ou de radiotherapie
GB0319793D0 (en) 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
EP1660065A2 (fr) * 2003-08-27 2006-05-31 Eli Lilly And Company Traitement des troubles profonds du developpement au moyen d'inhibiteurs de la recapture de la norepinephrine
WO2005025561A1 (fr) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions et methodes de traitement de l'intolerance orthostatique
EP1663398B1 (fr) * 2003-09-12 2009-11-25 Pfizer Limited Associations comprenant des ligands alpha-2-delta et des inhibiteurs du recaptage de la serotonine et de la noradrenaline
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
CA2548304A1 (fr) * 2003-12-12 2005-07-07 Eli Lilly And Company Traitement des bouffees de chaleur, des troubles du controle des impulsions et du changement de personnalite consecutifs a un etat pathologique general
ATE423772T1 (de) * 2003-12-23 2009-03-15 Lilly Co Eli Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
MXPA06012505A (es) 2004-04-30 2006-12-15 Warner Lambert Co Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central.
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
WO2006000903A2 (fr) * 2004-06-09 2006-01-05 Pfizer Limited Utilisation
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
EA200900930A1 (ru) 2004-08-13 2009-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Композиция таблетки с пролонгированным высвобождением, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
JP2008514689A (ja) * 2004-10-01 2008-05-08 ニューロキュア リミテッド Adhd、cfs、fmおよび鬱病の処置のためのロフェプラミンの薬学的な組成物の使用
WO2006105117A2 (fr) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Procede destine a traiter des troubles et des conditions au moyen d'inhibiteurs et d'antagonistes a peripherie restreinte
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
DK2135603T3 (da) 2005-11-22 2013-03-25 Orexigen Therapeutics Inc Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
ATE548034T1 (de) * 2006-06-28 2012-03-15 Chelsea Therapeutics Inc Pharmazeutische zusammensetzungen mit droxidopa
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
ES2500053T3 (es) 2007-03-09 2014-09-29 Chelsea Therapeutics, Inc. Composición farmacéutica que comprende droxidopa para el tratamiento de la fibromialgia
WO2008122019A1 (fr) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Amélioration de la tolérabilité de la mirtazapine et de la réboxétine par leur utilisation en combinaison
WO2008134325A1 (fr) * 2007-04-30 2008-11-06 Adolor Corporation Compositions de (-)-e-10-oh-nt, procédés de synthèse et utilisation
EP2514417A3 (fr) * 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa et composition pharmaceutique à base de celle-ci pour le traitement des troubles de l'humeur, des troubles du sommeil ou des troubles déficitaires de l'attention
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US8940315B2 (en) 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010011811A2 (fr) * 2008-07-24 2010-01-28 Theravance, Inc. Composés de 3-(phénoxyphénylméthyl)pyrrolidine
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (fr) * 2008-10-17 2010-04-22 Pfizer Limited Nouvelles utilisations pour l’esréboxétine et la réboxétine racémique
WO2010120910A1 (fr) * 2009-04-15 2010-10-21 Theravance, Inc. Composés 3-(phénoxypyrrolidin-3-yl-méthyle) hétéroaryle, 3-(phénylpyrrolidin-3-ylméthoxy) hétéroaryle, et 3-(hétéroarylpyrrolidin-3-ylméthoxy) hétéroaryle
CN105254552A (zh) * 2009-07-13 2016-01-20 施万生物制药研发Ip有限责任公司 3-苯氧基甲基吡咯烷化合物
US8273786B2 (en) * 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
EP2627630B1 (fr) 2010-10-11 2014-12-31 Theravance Biopharma R&D IP, LLC Inhibiteurs de la réabsorption de sérotonine
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状(姿勢反射異常)の治療剤
EP2858640B1 (fr) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition à être utilisée dans une méthode de traitement de la surcharge pondérale et de l'obésité dans de patients présentant un risque cardiovasculaire élevé
WO2016077724A1 (fr) 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Carbamates (2-amino-4(arylamino)phényl)
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (fr) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Utilisation de réboxétine pour traiter des troubles du système nerveux
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
EP3693020A1 (fr) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Formulations topiques enrichies en potassium pour le soulagement de la douleur et l'aide du sommeil
CR20220247A (es) * 2019-12-03 2022-08-18 Axsome Therapeutics Inc Uso de reboxetina para tratar los trastornos del sistema nervioso

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
CA2061665C (fr) 1991-02-25 2002-04-16 Mark Mortensen Foreman Traitement de troubles des voies urinaires inferieures
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (fr) * 1994-06-16 1997-06-03 David Taiwai Wong Potentialisation des effets de medicaments
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
CN1146421C (zh) 1996-03-25 2004-04-21 伊莱利利公司 治疗疼痛的组合物以及药物在制备所述组合物中的应用
EP0906104A4 (fr) 1996-03-25 2003-12-10 Lilly Co Eli Procede de traitement de la douleur
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US6479074B2 (en) * 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
EP0856312B1 (fr) 1996-11-27 1998-10-14 Dr. R. Pfleger Chemische Fabrik GmbH Utilisation du chlorure de trospium pour la fabrication d'un médicament pour le traitement de maladies de la vessie
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
EP1007041A4 (fr) 1997-04-11 2001-03-07 Lilly Co Eli Composition analgesique
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
AU5155198A (en) 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
UA57107C2 (uk) 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
CA2304112A1 (fr) 1997-09-23 1999-04-01 John Harrison Heiligenstein Traitement des troubles lies a l'hyperactivite et au deficit de l'attention
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
AU9692898A (en) 1997-10-17 1999-05-10 Eli Lilly And Company Potentiation of pharmaceuticals
CA2321157A1 (fr) * 1998-04-09 1999-10-21 Pharmacia & Upjohn Company Nouveaux traitements pour troubles nerveux
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
ATE283694T1 (de) * 1998-05-08 2004-12-15 Upjohn Co Neue arzneimittelkombinationen aus reboxetin und pindolol
AU4841599A (en) 1998-06-29 2000-01-17 Pharmaceuticals Applications Asociates, Llc Methods and transdermal compositions for pain relief
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
CN1660109A (zh) * 1999-07-01 2005-08-31 法玛西雅厄普约翰美国公司 高度选择性去甲肾上腺素再摄取抑制剂及其用途
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
JP2003523382A (ja) 2000-02-24 2003-08-05 ファルマシア・アンド・アップジョン・カンパニー 新規な薬物の組合せ
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
KR20020015363A (ko) 2002-02-27
US7723334B2 (en) 2010-05-25
EA200801805A1 (ru) 2008-12-30
CN1660109A (zh) 2005-08-31
SK19382001A3 (sk) 2002-07-02
AU771258B2 (en) 2004-03-18
BR0012136A (pt) 2002-06-11
ATE292971T1 (de) 2005-04-15
MXPA02000562A (es) 2002-07-02
US20020061910A1 (en) 2002-05-23
CN1660108A (zh) 2005-08-31
EA006652B1 (ru) 2006-02-24
ATE296634T1 (de) 2005-06-15
US6465458B1 (en) 2002-10-15
ES2242175T3 (es) 2005-11-01
DE60022916T2 (de) 2006-07-06
SK286668B6 (sk) 2009-03-05
KR20090087135A (ko) 2009-08-14
NZ533243A (en) 2005-12-23
TW200607511A (en) 2006-03-01
DE60026704T2 (de) 2006-10-19
EA200801806A1 (ru) 2008-12-30
HK1049630A1 (en) 2003-05-23
CZ20014625A3 (cs) 2002-08-14
AU5633700A (en) 2001-01-22
NO20016406L (no) 2002-02-19
EA200200111A1 (ru) 2002-06-27
SK286667B6 (sk) 2009-03-05
ATE320257T1 (de) 2006-04-15
US20060135520A1 (en) 2006-06-22
US7276503B2 (en) 2007-10-02
US20080103145A1 (en) 2008-05-01
SK286104B6 (sk) 2008-03-05
TWI293250B (en) 2008-02-11
TW200407146A (en) 2004-05-16
TW200607509A (en) 2006-03-01
DE60026704D1 (de) 2006-05-11
CN1289090C (zh) 2006-12-13
PT1196172E (pt) 2006-05-31
TWI298254B (en) 2008-07-01
US20080103147A1 (en) 2008-05-01
ES2258251T3 (es) 2006-08-16
NO20091168L (no) 2002-02-19
EA200400589A1 (ru) 2004-12-30
DE60022692T2 (de) 2006-06-22
ES2239311T3 (es) 2005-09-16
US6642235B2 (en) 2003-11-04
ATE305307T1 (de) 2005-10-15
US6987107B2 (en) 2006-01-17
EA011094B1 (ru) 2008-12-30
WO2001001973A2 (fr) 2001-01-11
CZ299847B6 (cs) 2008-12-10
DE60022917T2 (de) 2006-06-29
EP2087892A3 (fr) 2009-09-30
US20060135521A1 (en) 2006-06-22
ES2246487T3 (es) 2006-02-16
KR20050053799A (ko) 2005-06-08
KR20090087134A (ko) 2009-08-14
CL2008002866A1 (es) 2009-01-09
DE60022692D1 (de) 2005-10-20
US20060128705A1 (en) 2006-06-15
PT1459751E (pt) 2005-11-30
US20060142289A1 (en) 2006-06-29
US20080096890A1 (en) 2008-04-24
EA200501496A1 (ru) 2006-06-30
PT1632234E (pt) 2007-07-09
DE60023043T2 (de) 2006-06-14
NO20091158L (no) 2002-02-19
ES2247572T3 (es) 2006-03-01
CA2375908A1 (fr) 2001-01-11
NZ515885A (en) 2004-08-27
JP2006143749A (ja) 2006-06-08
DE60022916D1 (de) 2006-02-09
KR100704319B1 (ko) 2007-04-09
CA2643231A1 (fr) 2001-01-11
US7241762B2 (en) 2007-07-10
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
NO20016406D0 (no) 2001-12-28
EP1196172B1 (fr) 2006-03-15
MY137348A (en) 2009-01-30
TWI298255B (en) 2008-07-01
DK1459750T3 (da) 2005-08-15
KR100948757B1 (ko) 2010-03-23
DE60022917D1 (de) 2006-02-09
DE60035232D1 (de) 2007-07-26
CN1660110A (zh) 2005-08-31
ATE364386T1 (de) 2007-07-15
CO5190662A1 (es) 2002-08-29
TW200920378A (en) 2009-05-16
CL2008002868A1 (es) 2009-01-09
DE60019473D1 (de) 2005-05-19
EP2090312A1 (fr) 2009-08-19
HUP0201623A3 (en) 2004-12-28
ES2246485T3 (es) 2006-02-16
TW200607512A (en) 2006-03-01
ATE305306T1 (de) 2005-10-15
PT1459750E (pt) 2005-08-31
SK286669B6 (sk) 2009-03-05
EA200700232A1 (ru) 2007-06-29
EP1196172A2 (fr) 2002-04-17
DE60019473T2 (de) 2006-02-23
US20080103146A1 (en) 2008-05-01
ATE304358T1 (de) 2005-09-15
ATE305788T1 (de) 2005-10-15
DE60023043D1 (de) 2006-02-16
ES2258010T3 (es) 2006-08-16
HK1076723A1 (en) 2006-01-27
ATE319453T1 (de) 2006-03-15
KR100717660B1 (ko) 2007-05-15
AR035158A1 (es) 2004-05-05
PE20010684A1 (es) 2001-06-24
TWI245631B (en) 2005-12-21
DK1632234T3 (da) 2007-09-17
US20020128173A1 (en) 2002-09-12
US20090247528A1 (en) 2009-10-01
JP2003503450A (ja) 2003-01-28
US20060264436A1 (en) 2006-11-23
CN1379672A (zh) 2002-11-13
EP2087892A2 (fr) 2009-08-12
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
TWI294779B (en) 2008-03-21
AU2004202096B2 (en) 2005-10-20
CN1660111A (zh) 2005-08-31
CL2008002867A1 (es) 2009-01-09
PL352252A1 (en) 2003-08-11
US7338953B2 (en) 2008-03-04
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
GEP20094798B (en) 2009-10-26
ES2285645T3 (es) 2007-11-16
US20040147614A1 (en) 2004-07-29
IL187512A0 (en) 2008-06-05
US20030040464A1 (en) 2003-02-27
NO20091159L (no) 2002-02-19
EA008381B1 (ru) 2007-04-27
DE60035232T2 (de) 2008-02-14
SK286864B6 (sk) 2009-06-05
PL196996B1 (pl) 2008-02-29
WO2001001973A3 (fr) 2002-01-17
EA005029B1 (ru) 2004-10-28
AU2004202096A1 (en) 2004-06-10
IL187513A0 (en) 2008-06-05
TW200914027A (en) 2009-04-01
DE60026627T2 (de) 2007-02-01
DE60020613D1 (de) 2005-07-07
US6703389B2 (en) 2004-03-09
US6610690B2 (en) 2003-08-26
KR20060099544A (ko) 2006-09-19
JP2006321815A (ja) 2006-11-30
DE60020613T2 (de) 2006-03-16
US20020107249A1 (en) 2002-08-08
US7317011B2 (en) 2008-01-08
WO2001001973A8 (fr) 2001-05-17
DK1459749T3 (da) 2006-01-09
CN1205935C (zh) 2005-06-15
ES2246488T3 (es) 2006-02-16
TW200607510A (en) 2006-03-01
KR100935277B1 (ko) 2010-01-06
HUP0201623A2 (en) 2002-09-28
CA2375908C (fr) 2006-05-30

Similar Documents

Publication Publication Date Title
IL147246A0 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
AU8212901A (en) Deacetylase inhibitors
ZA200306488B (en) Benzamides and related inhibitors of factor Xa.
EP1423120A4 (fr) 2h-phtalazine-1-ones et procedes d'utilisation de celles-ci
GB9900416D0 (en) Inhibitors
HUP0103408A3 (en) Methods of using and compositions comprising dopamine reuptake inhibitors
HUP0200898A3 (en) Derivatives of venlafaxine and methods of preparing and using the same
MXPA03006260A (es) Derivados de amina sustituidos y metodos de uso.
HUP0201188A2 (en) Hemisynthetic method and new compounds
EP1223932A4 (fr) Composes et methodes
EP1146790A4 (fr) Composes et procedes
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
EP1313477A4 (fr) Composes et procedes
AU2002361861A8 (en) Selective 11beta-hsd inhibitors and methods for use thereof
EP1274424A4 (fr) Composes et procedes
PL364821A1 (en) Phenylpiperazines as serotonin reuptake inhibitors
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
AU8235601A (en) Dispenser and method of use
AU1334602A (en) Osteopontin-coated surfaces and methods of use
HK1048318B (zh) 取代的3-苯基-5-烷氧基-1,3,4-噁二唑-2-酮及其作為脂酶抑制劑的用途
EP1386674A4 (fr) Procede de nettoyage d'une structure, procede anticorrosion et structure mettant en oeuvre ceux-ci
EP1153022A4 (fr) Inhibiteurs de protease
AU1193199A (en) Arylpiperazines as serotonin reuptake inhibitors and 5-ht1dalpha antagonists
EP1263935A4 (fr) Scytonemine et ses procedes d'utilisation
ZA200110325B (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees